Hoʻomaʻo a me ka noiʻi ʻana o ka maʻi ʻaʻai holomua holomua: He aha ka mea ma ka Horizon?

Anter

• Nā therapies pahuhopu
• Nā lāʻau lapaʻau ma ka pae
• Nā lāʻau anti-angiogenesis
• Nā lāʻau Biosimilar
• Immunotherapy
• Nā mea kāohi PI3 kinase
• Hoʻonui i ka wānana a me ka nānā ʻana
• Komo i loko o kahi hoʻokolokolo hoʻokolokolo

Hiki ke mālama ʻia i ka maʻi ʻaʻai umauma Metastatic, akā pinepine pinepine ʻaʻole hiki ke hoʻōla ʻia. No kēia manawa, ʻo nā pahuhopu o ka mālama ʻana me ka hōʻemi ʻana i kāu mau hōʻailona, ​​ka hoʻomaikaʻi ʻana i kou ʻano o ke ola, a me ka hoʻolōʻihi ʻana i kou ola.

Hoʻopili maʻamau ka hoʻomaʻamaʻa ʻana i ka hoʻomaʻamaʻa hormone, chemotherapy, i hoʻoponopono ʻia i koho ʻia, a i ʻole ka hui pū ʻana o kēia mau mea.

Eia kekahi o nā hana i kēia manawa a me ka wā e hiki mai ana i hiki iā ʻoe ke manaʻo e lohe e pili ana inā ua loaʻa iā ʻoe kahi hōʻailona maʻi maʻi umauma holomua.

Nā therapies pahuhopu

Ua hoʻomohala nā kānaka noiʻi i kekahi mau lāʻau hou e kuhi ana i nā loli kikoʻī kikoʻī. ʻO kēia mau hoʻololi e ulu koke a hoʻolaha ʻia nā hunaola maʻi ʻaʻai. He ʻokoʻa kēia ma mua o ka chemotherapy, nā pahuhopu i nā hunaola āpau e ulu wikiwiki ana, e like me nā pūnaʻi maʻi ʻaʻai a me nā ʻola olakino.

Ua ʻae ʻia ka hapa nui o kēia mau lāʻau i mākaukau e mālama i ka maʻi ʻaʻai umauma metastatic. Ke aʻo ʻia nei nā poʻe ʻē aʻe i nā hoʻokolohua hoʻokolohua, a he nui hou aku i nā hoʻokolohua preclinical.

ʻO kekahi mau laʻana o nā hoʻoponopono e hoʻopili ʻia e:

• Lapatinib (Tykerb). ʻO kēia lāʻau lapaʻau kahi mea hōʻoki kine tyrosine kinase. Hana ia ma ka pale ʻana i nā enzyme e hāpai i ka ulu ʻana o ka cell. Loaʻa iā ia ma ke ʻano he pill āu e lawe ai i kēlā me kēia lā e mālama i ka maʻi ʻaʻai umauma metastatic. Hoʻohui ʻia paha me kekahi mau lāʻau chemotherapy a i ʻole nā ​​hoʻoponopono hormonal.
• Neratinib (Nerlynx). Ua ʻae ʻia kēia lāʻau e mālama iā HER2-maikaʻi maikaʻi i ka maʻi ʻaʻa umauma. Hōʻike kekahi mau noiʻi he mana paha i ka mālama ʻana i nā poʻe me ka maʻi ʻaʻai umauma metastatic pū kekahi.
• Olaparib (Lynparza). Ua ʻae ʻia kēia lapaʻau no ka HER2-maikaʻi ʻole maʻi maʻi umauma metastatic i nā poʻe i loaʻa iā BRCA hoʻololi kūʻē. Loaʻa ia ma ke ʻano he pilama i kēlā me kēia lā.

ʻO nā mea kāohi ʻo CDK4 / 6 kekahi papa o nā lāʻau lapaʻau i māka ʻia. Paʻa kēia mau lāʻau i kekahi mau protein i hiki ai i nā hunaola maʻi ʻaʻai ke ulu. ʻO Abemaciclib (Verzenio), palbociclib (Ibrance), a me ribociclib (Kisqali) nā mea kāohi iā CDK4 / 6 i ʻae ʻia e ka Food and Drug Administration (FDA) no ka mālama ʻana i ka maʻi ʻaʻai umauma. Hoʻohana ʻia lākou me ka hui pū me ka hormone therapy e mālama i nā maʻi maʻi umauma HR-maikaʻi a me HER2-maikaʻi ʻole.

Nā lāʻau lapaʻau ma ka pae

Nui a hewahewa nā maʻi i loaʻa e mālama ai i ka maʻi ʻaʻai umauma metastatic, akā ke mālama ʻia nei nā noiʻi ʻana e aʻo hou aʻe e pili ana i ka hana ʻana o kēia mau hunaola maʻi ʻea a me nā hoʻololi ʻana o nā gen. Ma lalo iho nei kekahi o nā ʻano mālama e noiʻi ʻia nei.

Nā lāʻau anti-angiogenesis

ʻO Angiogenesis ke kaʻina kahi i hana ʻia ai nā kīʻaha koko hou. Hoʻolālā nā lāʻau anti-angiogenesis e ʻoki i ka hāʻawi koko i nā moku. Hōʻalo kēia i nā hunaola maʻi ʻino o ke koko e pono ai e ulu.

ʻO ka anti-angiogenesis drug bevacizumab (Avastin) i kēia manawa ua ʻae ʻia ʻo FDA e mālama i nā maʻi ʻē aʻe. Ua hōʻike kēia lāʻau i kekahi pono i nā wahine me ka maʻi ʻaʻai nui o ka umauma, akā ua haʻalele ka FDA i ka ʻae no kēlā hoʻohana i ka makahiki 2011. ʻO Bevacizumab a me nā lāʻau anti-angiogenesis ʻē aʻe e hoʻomau nei i ka noiʻi no ka mālama ʻana i ka maʻi ʻaʻai umauma metastatic.

Nā lāʻau Biosimilar

ʻAno like nā lāʻau biosimilar me nā lāʻau lapaʻau inoa, akā e emi paha ke kumukūʻai. He koho lapaʻau kūpono lākou.

Ke aʻo ʻia nei nā lāʻau biosimilar he nui no ka maʻi ʻaʻai umauma. ʻO ke ʻano biosimilar o trastuzumab (Herceptin), kahi lāʻau chemotherapy, ʻo ia wale nō ka biosimilar i ʻae ʻia no ka mālama ʻana i ka maʻi ʻaʻai maʻi metastatic HER2-maikaʻi. Kapa ʻia ʻo trastuzumab-dkst (Ogivri).

Immunotherapy

ʻO ka Immunotherapy kahi ʻano o ka mālama ʻana e kōkua i ka ʻōnaehana pale pilikino ponoʻī o ke kino i ka luku ʻana i nā hunaola maʻi ʻaʻai.

ʻO kekahi papa o nā lāʻau immunotherapy ʻo ia nā mea hoʻopale PD1 / PD-L1. Ua ʻae ʻia ʻo Pembrolizumab (Keytruda) e mālama i ka maʻi ʻaʻa maʻi. Ke hoʻokolohua nei ia i nā hoʻokolohua hoʻokolohua e hoʻāʻo i kona pono i nā mea maʻi me ka maʻi ʻekolu o ka maʻi maʻi umauma metastatic.

Nā mea kāohi PI3 kinase

ʻO ka PIK3CA kōkua ka ʻāpana i ka mālama ʻana iā PI3 kinase, ka enzyme e ulu ai nā tumors. Hoʻonohonoho ʻia nā mea kāohi PI3 kinase e hoʻopau a kū i ka ulu ʻana o ka enzyme P13. Ke aʻo ʻia nei kēia no ka mālama ʻana i ka maʻi ʻaʻai umauma metastatic.

Hoʻonui i ka wānana a me ka nānā ʻana

Minamina, hiki i ka poʻe ke hoʻomohala i kekahi mau ʻano maʻi ʻaʻai. ʻO kēia ke kumu e hoʻōki i ka hana maikaʻi ʻana. Ke hoʻomohala nei nā mea noiʻi i nā ala hou e nānā ai i ka pane ʻana o nā mea maʻi i ka lāʻau.

Ke aʻo ʻia nei ke kālailai ʻia ʻana o ka DNA tumo (e ʻike ʻia he biopsy wai) ma ke ʻano he ʻano alakaʻi no ka mālama ʻana. Ke hoʻāʻo nei nā kānaka noiʻi inā he maikaʻi kēia hoʻokolohua i ka nānā ʻana i nā mea maʻi me ka maʻi ʻaʻai umauma metastatic a wānana pehea lākou e pane ai i ka lāʻau.

Komo i loko o kahi hoʻokolokolo hoʻokolokolo

ʻO ke komo ʻana i ka hoʻokolohua hoʻokolohua hiki ke kōkua i ka poʻe noiʻi e ʻike inā holo pono nā mālama hou. Inā hoihoi ʻoe i ka hui ʻana i hoʻokahi, kahi hoʻomaka maikaʻi ʻo ClinicalTrials.gov, kahi waihona hulina o nā noiʻi e hoʻopaʻa nei a puni ka honua. E nānā pū i nā hana e like me ka Metastatic Breast Cancer Project. Hoʻopili kēia paepae pūnaewele i ka poʻe i loaʻa i ka maʻi ʻaʻai umauma metastatic me nā ʻepekema e hoʻohana nei i ka ʻenehana e hoʻopaʻa i nā kumu o ka maʻi ʻaʻai.

E kamaʻilio me kāu kauka lawelawe e ʻike inā kūpono ke komo ʻana i ka hoʻokolohua hoʻokolohua nāu.Hiki iā lākou ke kōkua iā ʻoe e hoʻoholo inā kūpono ʻoe a kōkua iā ʻoe e kākau inoa.